PFS
Fig. 1 · Panel Kaplan_Meier_plot_of_PFS_by_treatment_group
Panel Kaplan_Meier_plot_of_PFS_by_treatment_group 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Kensei Yamaguchi, Hirokazu Shoji, Hisateru Yasui, Eiji Oki, Daisuke Sakai, Tetsuya Hamaguchi, Akihito Tsuji, Takashi Oshima, Masahiro Tsuda, Keiko Minashi, Jianning Yang, Abraham Guerrero, Yoko Ueno, Maria Matsangou, Georgia Gourgioti, Yuka Nakanishi, Satomi Furuki, Kana Kuwamoto, Shunsuke Yamada, Kohei Shitara
Gastric Cancer 29(4) 777-787
BACKGROUND: Zolbetuximab is a monoclonal antibody targeting claudin 18 isoform 2 (CLDN18.2) approved for first-line treatment of CLDN18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Here, we report efficacy and safety outcomes from the combined Japanese subgroup analysis of SPOTLIGHT and GLOW. METHODS: Global, double-blind, phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) trials investigated zolbetuximab plus chemotherapy versus placebo plus chemotherapy in patients with CLDN18.2-positive, HER2-negative, LA unresectable or metastatic gastric or GEJ adenocarcinoma. The primary endpoint in both trials was progression-free survival (PFS); overall survival (OS) was a key secondary endpoint. RESULTS: Of 1072 patients enrolled, 116 Japanese patients (SPOTLIGHT, n = 65; GLOW, n = 51) comprised the combined Japanese subgroup. The baseline characteristics of Japanese patients were generally similar to those of the overall study populations. In the combined Japanese subgroup, PFS was improved with zolbetuximab plus chemotherapy versus placebo plus chemotherapy (20.53 months [95% confidence interval (CI) 12.09-not estimable] versus 8.28 months [95% CI 6.57-9.07]). Median OS was 23.06 months (95% CI 16.49-25.49) in the zolbetuximab group versus 16.53 months (95% CI 10.38-18.33) in the placebo group. No new safety signals were observed. CONCLUSIONS: In Japanese patients, zolbetuximab plus chemotherapy improved PFS versus placebo plus chemotherapy and showed a numerical improvement in OS. These results support zolbetuximab plus chemotherapy as a potential new standard-of-care first-line option for Japanese patients with CLDN18.2-positive, HER2-negative, LA unresectable or metastatic gastric or GEJ adenocarcinoma.
2 个 Figure · 3 个 KM 面板
Fig. 1 PFS by IRC in the combined Japanese subgroup. a Kaplan–Meier plot of PFS by treatment group. b Subgroup analyses of PFS by treatment group. CI confidence interval, GEJ gastroesophageal junction, HR hazard ratio, IRC independent review committee, NE not estimable, PFS progression-free survival
Fig. 1 · Panel Kaplan_Meier_plot_of_PFS_by_treatment_group
Panel Kaplan_Meier_plot_of_PFS_by_treatment_group 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 OS in the combined Japanese subgroup. a Kaplan–Meier plot of OS by treatment group. b Subgroup analyses of OS by treatment group. CI confidence interval, GEJ gastroesophageal junction, HR hazard ratio, NE not estimable, OS overall survival
这些图片未产生 KM 曲线结果,不在主页面重复展示。